ZW251

About Zymeworks

Zymeworks is a clinical-stage biotech company with a mission to turn scientific innovation into meaningful impact for patients with difficult-to-treat diseases. The company has achieved a significant milestone with the first approval of its partnered asset, zanidatamab (Ziihera®), and is advancing a diverse internal pipeline of next-generation ADCs and multispecific antibodies. Its strategy is built on a dual approach: generating future royalty and milestone cash flows from a portfolio of partnered assets while reinvesting in high-value internal R&D to fuel long-term growth and shareholder returns.

Therapeutic Areas

Other Hepatocellular carcinoma (HCC) Drugs